27 results on '"Crown John"'
Search Results
2. Carcinoma of unknown primary (CUP): an update for histopathologists
3. Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
4. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
5. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells
6. Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study
7. The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells
8. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
9. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
10. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
11. Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden
12. High-Dose Chemotherapy for Breast Cancer in Europe : From Fashion to Randomization
13. High-dose chemotherapy with peripheral blood progenitor autografting
14. Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
15. EGFR and HER2 inhibition in pancreatic cancer
16. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
17. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
18. Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer
19. Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study
20. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
21. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
22. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
23. Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue
24. Prevalence and prognostic and predictive relevance of PRAME in breast cancer
25. High-dose chemotherapy with peripheral blood progenitor autografting
26. Erratum to: Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
27. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.